OLMA
Olema Pharmaceuticals, Inc.Healthcare · $745M market cap
Verdict
We can't put a fair value on OLMA right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.
Business quality
0 of 5 clear the 10% bar. What are the Big Five?
Follow OLMA
Track it on your watchlist and see the full analysis. Free.
Create a free accountSuperinvestors
None of the investors we track holds OLMA right now. In Q1 2026, 1 sold out. Who we track
Moves in Q1 2026
Sold out: Polen Capital Management
Insider activity
Since Sep 1, 2026: no open-market purchases and 1 other filing (stock awards, tax withholding and similar). Why purchases matter
Other filings
About Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER)…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works